



The Kentuckiana Health Collaborative is pleased to announce the release of the 2015 Consolidated Measurement Report. Private reports were sent to health care providers and group practices throughout Kentuckiana to provide feedback on the quality of care their patients received on select measures. For this report, the quality of care data were aggregated across providers at the county and regional level. Aetna Better Health of Kentucky, Anthem Blue Cross Blue Shield, Humana Health Plan of Kentucky, Passport Health Plan, and WellCare Health Plan of Kentucky provided claims data for this report.

	Kentuckiana ¹		National Averages ⁴		
	Average ²	Benchmark ³	PPO ⁵	HMO ⁵	Medicaid
Preventive Care Management					
Breast Cancer Screening Denominator	24,220	2,297			
Mammogram Performed	79%	99%	70%	77%	59%
Cervical Cancer Screening Denominator	42,540	3,642			
Pap Test Performed	72%	98%	74%	76%	60%
Chlamydia Screening Denominator, Overall	9,618	722			
Screening Performed	57%	92%	43%	47%	55%
Colorectal Cancer Screening Denominator	55,608	4,604			
Appropriate Screening	55%	82%	58%	64%	-
Acute Care Management					
Low Back Pain Denominator	3,896	251			
Appropriate Use of Imaging Study	67%	95%	75%	75%	75%
Adults with Acute Bronchitis Denominator	2,693	136			
No Antibiotic Rx	18%	49%	26%	28%	29%
Chronic Disease Care Management					
Diabetes Denominator	21,084	3,939			
HbA1c Tested	92%	100%	88%	91%	86%
HbA1c Control (Tested < 8%) ⁶	63%	92%	53%	58%	47%
HbA1c Poor Control (Tested > 9%) ⁶	22%	0%	37%	31%	44%
Nephropathy Monitored	86%	100%	80%	85%	81%
Eye Exam (Retinal) Performed	44%	67%	49%	56%	54%
Diabetes Screening Composite*	74%	87%	-	-	-
Asthma Appropriate Medication Denominator, Overall	2,644	506			
Appropriate Medication	91%	100%	90%	91%	84%
Asthma Controller Medication Ratio Denom., Overall	1,829	76			
Controller Medication Ratio	79%	100%	76%	78%	59%
Asthma Medication Management Denom., Overall	1,732	57			
Med. Management (on Controller >50%)	66%	93%	-	-	-
Med. Management (on Controller >75%)	41%	75%	46%	45%	31%
COPD Denominator	2,886	218			
Use of Spirometry Testing	40%	82%	41%	43%	31%
AMI Denominator	349	5			
Persistence of Beta-Blocker Tx after AMI	78%	100%	82%	84%	83%



	Kentuckiana ¹		National Averages ⁴		
	Average ²	Benchmark ³	PPO ⁵	HMO ⁵	Medicaid
Chronic Disease Care Management					
Antidepressant Medication Denominator	2,805	110			
Effective Continuation Phase Treatment	50%	79%	51%	50%	37%
Effective Acute Phase Treatment	66%	92%	66%	66%	52%
Hospitalization for Mental Illness Denominator	1,146	57			
Follow-up within 7 Days after Discharge	41%	67%	50%	53%	44%
Follow-up within 30 Days after Discharge	58%	100%	69%	71%	63%
Pediatric Care Management					
Childhood Immunization Denominator	5,258	160			
DTaP	65%	90%	80%	87%	78%
Influenza	52%	90%	64%	67%	51%
Polio	73%	95%	86%	92%	89%
MMR	91%	100%	89%	92%	90%
HiB (H Influenza Type B)	81%	98%	88%	94%	89%
Hepatitis B	32%	41%	78%	89%	89%
Chicken Pox	91%	100%	89%	92%	90%
PCV (Pneumococcal conjugate)	65%	92%	80%	88%	78%
Hepatitis A	74%	81%	82%	84%	83%
Rotavirus	57%	90%	75%	81%	68%
Adolescent Immunization Denominator	3,910	143			
All Recommended	75%	95%	62%	71%	71%
Well-Child Visits 0-15 m.o.	4,678	144			
At Least 6 Visits	71%	100%	77%	78%	59%
Well-Child Visits 3-6 y.o.	19,590	891			
At Least 1 Visit	82%	93%	72%	76%	72%
Pediatric Pharyngitis Denominator	4,377	508			
Group A Strep. Test	86%	100%	80%	82%	70%
Pediatric URI Denominator	4,360	454			
No Antibiotic Rx	79%	100%	85%	87%	87%

¹ Performance of providers in Kentucky's Jefferson, Oldham, and Bullitt counties and Indiana's Floyd, Clark, Harrison, and Scott counties.

² The total rate across the measure's aggregate denominator (i.e., eligible patients or events) for the region.

³ The average rate for the top-ranked eligible (at least 5 patients) providers, whose combined patients account for 10% of the total population from eligible providers. "-" means that data are not available for comparison.

⁴ National averages are from the NCQA's report, "The State of Health Care Quality 2015," available at www.ncqa.org.

⁵ PPO and HMO national averages are from commercial health plans.

⁶ These measures only include patients who received the listed test and whose most recent lab values are present in health plan data. This differs from HEDIS specifications.

* This is a composite of Eye Exam (Retinal), HbA1c Testing, and Nephropathy Monitoring. The three measures receive equal weight.




■ Kentuckiana Average
 ■ Kentuckiana Benchmark
 ■ National PPO Average
 ■ National Medicaid Average


Pediatric Care Management

Preventive Care Management


Childhood Immunizations




Well-Child Care




Adult Screening




Childhood Immunizations (continued)



Antibiotics and Testing




Adult Screening (cont.)




Chronic Disease Management

Acute Care Management


Diabetes




Asthma and COPD



Mental Illness and Depression



Antibiotics Imaging





Data for counties with a denominator of less than 250 are suppressed. Data for an individual provider are included in the totals for each county for which the provider had an associated practice location.

	Kentucky Counties			Indiana Counties			
	Bullitt	Oldham	Jefferson	Floyd	Clark	Harrison	Scott
Preventive Care Management							
Breast Cancer Screening Denominator	812	743	21,040	1,104	1,048	-	475
Mammogram Performed	67%	72%	79%	77%	78%	-	66%
Cervical Cancer Screening Denominator	1,366	1,325	37,949	1,616	1,299	310	811
Pap Test Performed	55%	61%	72%	72%	74%	71%	65%
Chlamydia Screening Denominator, Overall	279	460	8,741	285	305	-	-
Screening Performed	48%	61%	58%	47%	62%	-	-
Colorectal Cancer Screening Denominator	2,353	1,969	47,637	2,613	2,619	603	1,163
Appropriate Screening	52%	51%	56%	50%	51%	46%	43%
Acute Care Management							
Low Back Pain Denominator	-	-	3,252	-	-	-	-
Appropriate Use of Imaging Study	-	-	67%	-	-	-	-
Adults with Acute Bronchitis Denominator	-	-	2,145	-	-	-	-
No Antibiotic Rx	-	-	19%	-	-	-	-
Chronic Disease Care Management							
Diabetes Denominator	1,175	762	18,138	929	1,000	-	457
HbA1c Tested	93%	92%	92%	91%	90%	-	88%
HbA1c Control (Tested < 8%) ¹	62%	68%	61%	73%	73%	-	-
HbA1c Poor Control (Tested > 9%) ¹	25%	17%	23%	13%	14%	-	-
Nephropathy Monitored	84%	81%	86%	86%	82%	-	83%
Eye Exam (Retinal) Performed	43%	40%	45%	41%	39%	-	29%
Diabetes Screening Composite*	73%	71%	75%	73%	70%	68%	67%
Asthma Appropriate Medication Denominator, Overall	-	-	2,470	-	-	-	-
Appropriate Medication	-	-	91%	-	-	-	-
Asthma Controller Medication Ratio Denom., Overall	-	-	1,673	-	-	-	-
Controller Medication Ratio	-	-	79%	-	-	-	-



	Kentucky Counties			Indiana Counties			
	Bullitt	Oldham	Jefferson	Floyd	Clark	Harrison	Scott
Chronic Disease Care Management							
Asthma Medication Management Denom., Overall	-	-	1,568	-	-	-	-
Med. Management (on Controller >50%)	-	-	66%	-	-	-	-
Med. Management (on Controller >75%)	-	-	41%	-	-	-	-
COPD Denominator	-	-	2,255	-	-	-	-
Use of Spirometry Testing	-	-	41%	-	-	-	-
AMI Denominator	-	-	293	-	-	-	-
Persistence of Beta-Blocker Tx after AMI	-	-	78%	-	-	-	-
Antidepressant Medication Denominator	-	-	2,508	-	-	-	-
Effective Continuation Phase Treatment	-	-	50%	-	-	-	-
Effective Acute Phase Treatment	-	-	66%	-	-	-	-
Hospitalization for Mental Illness Denominator	-	-	977	-	-	-	-
Follow-up within 7 Days after Discharge	-	-	40%	-	-	-	-
Follow-up within 30 Days after Discharge	-	-	58%	-	-	-	-
Pediatric Care Management							
Childhood Immunization Denominator	-	-	4,953	-	-	-	-
DTaP	-	-	65%	-	-	-	-
Influenza	-	-	52%	-	-	-	-
Polio	-	-	73%	-	-	-	-
MMR	-	-	91%	-	-	-	-
HiB (H Influenza Type B)	-	-	81%	-	-	-	-
Hepatitis B	-	-	33%	-	-	-	-
Chicken Pox	-	-	91%	-	-	-	-
PCV (Pneumococcal conjugate)	-	-	65%	-	-	-	-
Hepatitis A	-	-	75%	-	-	-	-
Rotavirus	-	-	57%	-	-	-	-
Adolescent Immunization Denominator	-	-	3,599	-	-	-	-



	Kentucky Counties			Indiana Counties			
	Bullitt	Oldham	Jefferson	Floyd	Clark	Harrison	Scott
Pediatric Care Management							
Adolescent Immunization Denominator	-	-	3,599	-	-	-	-
All Recommended	-	-	75%	-	-	-	-
Well-Child Visits 0-15 m.o.	-	-	4,411	-	-	-	-
At Least 6 Visits	-	-	71%	-	-	-	-
Well-Child Visits 3-6 y.o.	738	810	18,127	463	310	-	-
At Least 1 Visit	77%	80%	82%	79%	80%	-	-
Pediatric Pharyngitis Denominator	-	252	3,908	-	-	-	-
Group A Strep. Test	-	88%	86%	-	-	-	-
Pediatric URI Denominator	-	251	3,960	-	-	-	-
No Antibiotic Rx	-	86%	79%	-	-	-	-

¹ These measures only include patients who received the listed test and whose most recent lab values are present in health plan data. This differs from HEDIS specifications.


* This is a composite of Eye Exam (Retinal), HbA1c Testing, and Nephropathy Monitoring. The three measures receive equal weight.



■ Bullitt
 ■ Oldham
 ■ Jefferson
 ■ Floyd
 ■ Clark
 ■ Harrison
 ■ Scott


Preventive Care Management

Adult Screening




Acute Care Management

Testing and Antibiotic Use




Pediatric Care Management


Well-Child Care



Immunizations




Testing and Antibiotic Use




Chronic Disease Management

Diabetes



COPD





All provider and community measures use criteria established by the Healthcare Effectiveness Data and Information Set (HEDIS). HEDIS is a set of standardized performance measures designed to ensure that purchasers and consumers have the information they need to reliably compare the performance of health care plans (see www.ncqa.org for more information). This report used administrative data only. No chart review was conducted

MEASURE	NQF#	ELIGIBLE POPULATION	NUMERATOR CRITERIA
Preventive Care Management			
Breast Cancer Screening	2372	Females 52 to 74 years of age	At least one mammogram between 10/01/2012 and 12/31/2014
Cervical Cancer Screening	32	Females 21 to 64 years of age	At least one Pap test between 2012-2014, or if over 30 at testing, Pap test + HPV test between 2010 and 2014
Chlamydia Screening	33	Females 16 to 24 years of age identified as sexually active	At least one chlamydia test during 2014
Colorectal Cancer Screening	34	Patients 51 to 75 years of age	Any of: (1) A fecal occult blood test in 2014, (2) flexible sigmoidoscopy between 2010 and 2014, or (3) colonoscopy between 2005 and 2014
Pediatric Care Management			
Childhood Immunization	38	Children who turned 2 years old during 2014	All recommended vaccines by second birthday
Immunization for Adolescents	1407	Children who turned 13 years old during 2014	Before 13th birthday, one dose of meningococcal and one dose of either Tdap vaccine or one Td vaccine
Well-Child Visits in First 15 Months of Life	1392	Children who turned 15 months old during 2014	At least 6 well-child visits with a PCP in 2014
Well-Child Visits in Years 3-6	1516	Children 3 to 6 years of age during 2014	At least one well-child visit with PCP during 2014
Pediatric Pharyngitis Testing	2	Patients 2 to 18 years of age diagnosed with pharyngitis and dispensed an antibiotic	A group A streptococcus test administered between 3 days before and 3 days after the episode start date
Pediatric Upper Respiratory Tract Infection Treatment	69	Patients 3 months to 18 years of age with only a Dx of Upper Respiratory Infection during intake	Not dispensed antibiotic Rx on or up to 3 days after the episode start date
Acute Care Management			
Low Back Pain	52	Patients 18 to 50 years of age who had ED or outpatient visit with primary Dx of low back	Did not receive imaging study (X-Ray, MRI, CT) on or up to 28 days after episode start date
Acute Bronchitis in Adults	58	Patients 19 to 64 years of age diagnosed with acute bronchitis	Not dispensed antibiotic Rx on or up to 3 days after the episode start date



MEASURE	NQF#	ELIGIBLE POPULATION	NUMERATOR CRITERIA
Chronic Disease Management			
Comprehensive Adult Diabetes Care	57	Patients 18 to 75 years of age with diabetes (type 1 or type 2)	<p>HbA1c: An HbA1c test performed in 2014</p> <p>Eye Exam: An eye screening for diabetic retinal disease; requires a retinal or dilated eye exam by eye care professional in 2014 or negative retinal or dilated eye exam by eye care professional in 2013</p> <p>Nephropathy: Nephropathy screening test <i>or</i> evidence of nephropathy in 2014</p> <p>Screening Composite*: This is a composite of Eye Exam (Retinal), HbA1c Testing, and Nephropathy Monitoring. The three measures are given equal weight.</p>
	55		
	62		
HbA1c Control in Patients with Diabetes*	575	As above, but only includes patients for whom HbA1c lab values from 2014 are available	HbA1c Control: Most recent HbA1c from test in 2014 is < 8.0%
Asthma - Use of Appropriate Medication and Medication Management	59	Patients 5 to 64 years of age with persistent asthma	HbA1c Poor Control: Most recent HbA1c from test in 2014 is > 9.0%
	36		Appropriate Med.: At least one Rx for asthma controller dispensed during
	1800		Med. Ratio: Asthma controllers compose \geq 50% of total asthma medications
	1799		Med. Management: Member remained on controller medication for at least
	1799		Med. Management 75: As above, but for \geq 75% of the treatment period
Spirometry Testing in COPD Assessment and Diagnosis	577	Patients at least 42 years of age with newly diagnosed or active (2 years since Dx or Tx) COPD	At least one claim/encounter with spirometry testing between 730 days before and 180 days after the episode start date
Persistence of Beta-Blocker Treatment after Heart Attack	71	Patients at least 18 years of age discharged with AMI from acute inpatient setting between 7/01/2013 and 6/30/2014	A 180-day course of treatment with beta blockers following discharge
Follow-up after Hospitalization for Mental Illness	576	Patients at least 6 years of age at discharge who were hospitalized for selected mental health disorders in 2014	7: Received follow-up with mental health practitioner within 7 days of 30: As above, but within 30 days of discharge
Antidepressant Medication Management	105	Patients at least 18 years of age and up by 4/30/14 who were diagnosed with a new episode of depression <i>and</i> treated with medication	Acute Phase: At least 84 days (12 weeks) of continuous treatment within 114 days of date medication dispensed (up to 30 gap days allowed)
			Continuation Phase: 180+ days of continuous treatment within 231 days

* This measure only includes patients who received the listed test and whose most recent lab values are present in health plan data. This differs from HEDIS specifications